中國優材(01885.HK)指進一步延期寄發2020年度業績 續停牌
中國優材(01885.HK)公布,進一步延遲刊發2020年全年業績及寄發2020年年報。
公司就2020年全年業績在中國進行的若干實地審計工作的進度,因河北省於2021年1月至2021年3月初期間實施停工及出行限制以抗擊疫情而受到中斷。自2021年4月起,集團已涉及一項由該部門對一名前供應商及前股東進行的調查事項,據此,集團已被該部門要求協助進行調查事項。
公司之主要業務為銷售其自產經處理楊木板材以及為向集團提供原木板材加工的客戶提供木材處理工藝服務。收入主要來自銷售其自產經處理板材。
公司續停牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.